About

Selux Diagnostics focuses on antibiotic susceptibility testing (AST) to address the growing issue of antimicrobial resistance (AMR). The company provides healthcare providers, such as hospitals, with rapid and accurate testing results that determine how bacteria respond to various antibiotics. This technology allows for simultaneous testing against all relevant antibiotics, which is a notable advancement in a field that has seen little progress in recent years. By delivering faster diagnostic results and comprehensive susceptibility profiles, Selux helps healthcare professionals prescribe the most effective antibiotics, reducing the risk of incorrect or unnecessary prescriptions. The goal of Selux Diagnostics is to preserve the effectiveness of antibiotics for future generations and combat the global health crisis posed by AMR.

Simplify's Take

What believers are saying

• Recent FDA clearances and substantial funding rounds, including a $48 million investment, position Selux for aggressive expansion and product development.
• The addition of industry veterans to the board and advisory roles enhances the company's strategic direction and credibility in the healthcare sector.
• Selux's rapid and accurate AST technology can significantly improve patient outcomes, reduce hospital stays, and combat the global antibiotic resistance crisis, making it a highly impactful place to work.

What critics are saying

• The high costs associated with developing and commercializing advanced diagnostic technologies could strain financial resources.
• The competitive landscape in healthcare diagnostics is intense, with larger, more established companies potentially overshadowing Selux's innovations.

What makes Selux Diagnostics unique

• Selux Diagnostics offers the only single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies, setting it apart from competitors.
• Their Next Generation Phenotyping (NGP) platform significantly increases the speed and accuracy of targeted antibiotic therapies, a breakthrough in a field that has seen little innovation in decades.
• Selux's comprehensive testing against all commercially relevant antibiotics at once is a unique feature that addresses a critical need in combating antimicrobial resistance.

Help us improve and share your feedback! Did you find this helpful?

YesNo